Finance & Banking
BIO Investment & Growth Summit 2026
T
he new biotech CEO and investor conference from BIO, the BIO Investment & Growth Summit.
93Voices
13Underwriters
0Exhibitors
29On the bill · sessions
101Companies · in total
The Voices
Programmed at BIO, in alphabetical order.Abhijit Bhatia
Chief Operating Officer · Rakuten Medical
Amir Hefni
CEO · Resolution Therapeutics
Andrew Hall
CEO · Consano Bio
Andrew Meadow
Founding Partner · Health Innovation Capital_Andrew Meadow
Andrew Rymer
Partner · Centerview Partners LLC
Andy Lee
Co-founder & CBO · Vincere Biosciences Inc
Anna Abram
Senior Advisor, Health Care Policy and Legislation · Akin
Anthony Japour
CEO and President · iTolerance, Inc.
Arda Ural
Americas Life Sciences Leader · Ernst & Young, LLP
Asish Xavier
Vice President, Venture Investments · Johnson & Johnson Innovation
Atul Deshpande
Chief Executive Officer · IMMEDIATE TX
Bernard Cooney
Senior Partner, Capital Formation · Flagship Pioneering
Carl Schmid
Executive Director · HIV+Hepatitis Policy Institute
Chris Dokomajilar
Founder and CEO · DealForma
Christer Rosén
Chairman & CEO · Jupiter Neurosciences, Inc.
Christopher Reyes
CEO & Founder · Bloom Science
Christopher Schaber
President & CEO · Soligenix, Inc.
Christopher Thanos
President and CEO · XDemics Corporation
Courtney Miller
Co-Founder, Myosin Therapeutics; Professor, Department of Molecular Medicine, Department of Neuroscience · UF Scripps Biomedical Research
Craig Shepherd
Senior Managing Director · Blackstone Life Sciences
Daniel Brog
Managing Director · Locust Walk
Daniel Haders
CEO · Model Medicines
— and 71 more, by name unsung —
Underwritten By
The houses behind the program. Tiers as disclosed.AvantorPremier
BIOPartner
Blaise Group InternationalConference
CHUBBConference
Corporate TravelerConference
CytovancePremier
freemindPartner
GATCConference
ScendeaConference
Southern Star ResearchConference
Syneos HealthPremier
The Money Channel NYCConference
The Programme
Selected from 29 sessions on the bill.- 01:30 PM 02:15 PM
Session: The High-Impact Investment Landscape in Immunology & Inflammation
- 01:30 PM – 02:15 PM
The High-Impact Investment Landscape in Immunology & Inflammation
Expansion in the target landscape, from TL1A and beyond, has accelerated progress in I&I drug development with multibillion-dollar M&A across the past two years attracting more fun…
- 01:30 PM – 02:30 PM
Spotlight on Innovation
The Innovation Stage offers a mix of programming showcasing biotech companies seeking breakthrough treatments and the University of Florida.
- 02:00 PM – 02:30 PM
Gator Dynamism: University of Florida’s Innovation in Biotech
- 02:30 PM 03:15 PM
Session: Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines
- 02:30 PM – 03:15 PM
Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines
GLP-1 analogs have rewritten treatment standards and changed patients’ expectations related to obesity, yet even more tantalizing is growing evidence they could hold the key to bro…
- 02:45 PM 03:30 PM
Session: Derisking Commercialization Plans to Attract Investment
- 02:45 PM – 03:30 PM
Derisking Commercialization Plans to Attract Investment
As biotech funding dynamics evolve, investors are seeking capital models that reward commercial discipline and strategic partnership. Traditional venture pathways are giving way to…
- 03:45 PM 04:30 PM
Session: Balancing Global Opportunities and Trade Policy Risks
Intermission
Part the Second · For the Buyer
What does it mean when 101 companies show up — and 1 bet on three roles at once?
“101 companies. one are betting more than once.”
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
1All threespeak · spons · exh
12Sponsoringsponsor only
0Exhibitingexhibitor only
88Speakingspeaker only
The Triple-Threat
82% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
- C-suite4649%
- Founder / Owner1011%
- VP-level44%
- Director / Head of1617%
- Manager / Lead44%
- Research / Science11%
- Advisor / Investor33%
- Other roles910%
Of 93 on the bill · classified by free-text title
- 01Syneos HealthSp·P1V
- 02AvantorSp·P
- 03BIOSp·P
- 04Blaise Group InternationalSp·C
- 05ChubbSp·C
- 06Corporate TravelerSp·C
- 07CytovanceSp·P
- 08freemindSp·P
- 09GATCSp·C
- 10Johnson & Johnson Development CorporationSp·P
- 11ScendeaSp·C
- 12Southern Star ResearchSp·C
- 13The Money Channel NYCSp·C
- 14UF Innovate, University of Florida2V
conference7
54% of 13
partner2
15% of 13
premier4
31% of 13
- BIO International 2026June 22, 2026 · San Diego+ 4 shared